Namuscla 167 mg hard capsules, Mexiletine 62 mg hard capsules, Mexiletine 83 mg hard capsules
MEX-NM-303
Approved small_molecule active
Quick answer
Namuscla 167 mg hard capsules, Mexiletine 62 mg hard capsules, Mexiletine 83 mg hard capsules for Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2) is a Approved program (small_molecule) at Lupin Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lupin Europe GmbH
- Indication
- Myotonic disorders: Nondystrophic myotonias (NDM) or myotonic dystrophies (DM, type 1 or type 2)
- Phase
- Approved
- Modality
- small_molecule
- Status
- active